Ezose Sciences Management Team

Ezose Sciences is a young, highly motivated and dynamic company. The focus of Ezose Sciences is to act as a glycan analysis partner and contribute to advancing biomarker medical research. This research includes discovery of biomarkers and therapeutics, via the application of its proprietary platform technologies that enable high-throughput glycan analysis. Ezose Sciences’ management team has decades of experience in biological research. More than half of staff members hold doctorate degrees in Molecular Biophysics, Biochemistry and related scientific fields.

Ryuichi Kiyama, Ph.D.
Chairman & CEO

Dr. Ryuichi Kiyama serves as Chairman and Chief Executive Officer of Ezose Sciences. He is also a Vice President of Shionogi & Co., Ltd., where he serves as Head of the Diagnostics Division that oversees Ezose’s operations. Dr. Kiyama has over 25 years experience in the pharmaceutical and diagnostics industries. Previously, he held several senior management positions in Shionogi, including Head of Medicinal Chemistry and Head of Research Planning within Discovery Research Laboratories, and corporate roles as Head of Corporate Planning and Head of Business Development. Dr. Kiyama earned his Ph.D. in Medicinal Chemistry from Kyushu University, Japan.

Scott A. Siegel, Ph.D.
Chief Operating Officer

Dr. Scott Siegel serves as Ezose Sciences’ Chief Operating Officer and head of Business Development, bringing over 25 years experience in the biotechnology and pharmaceutical industries to the role. Prior to joining Ezose he was Vice President of Corporate Development for Redpoint Bio, a publically traded biotechnology company based in NJ. Previously, he spent eight years with Johnson & Johnson in both New Business Development and Worldwide Strategic Marketing, with responsibilities for the in-licensing of new pharmaceutical products and technologies. Earlier in his career he served in various R&D capacities including Senior Director, Preclinical Research and Development for Phytera, Inc.; Associate Director, Immunobiology Research for Centocor, Inc.; and Section Leader, Immunodiagnostics Development for Becton Dickinson and Co. He also previously served as Adjunct Associate Professor of Microbiology at the University of Pennsylvania. Dr. Siegel is one of the inventors of Remicade® (Infliximab), a therapy for rheumatoid arthritis and other inflammatory disorders. He earned his Ph.D. in Biochemistry from the State University of New York, Downstate Medical Center, and completed his postdoctoral studies in the Department of Pharmacology at Yale University School of Medicine.

Hidehisa Asada, Ph.D., M.B.A.
Vice President, Research and Development

Dr. Hidehisa Asada’s overall responsibility is for the Company’s Research and Development along with managing the product line. Dr. Asada joined Ezose Sciences Inc. since its incorporation in March, 2009 and serves as a Company Officer. Prior to joining Ezose Sciences Inc., he had been working at Shionogi & Co., Ltd. both for Therapeutics and Diagnostics, on research and licensing projects. As a project leader of Diagnostics, he led the team for the global development of Brain Natriuretic Peptide test at Oslo University, Glasgow University, Mayo Clinic and Framingham Heart Study. Since 2007, he initiated the project for the establishment of the technology based spin-off company with Hokkaido University and launched Ezose Sciences Inc. with the foundation by Shionogi & Co., Ltd. and Sumitomo Bakelite Co., Ltd. Dr. Asada received a Ph.D. in Immune Biology from Gifu Pharmaceutical University and an M.B.A. from Kansei Gakuin University in Japan.

Your Next Step

Our team will be happy to discuss your individual research needs and to provide additional details about our biomarker research programs and complete suite of glycan analysis services. Contact Ezose Sciences today to get started.